An announcement from Karolinska Development AB ( ($SE:KDEV) ) is now available. Karolinska Development AB’s portfolio company, SVF Vaccines, has ...

The World Health Organisation’s International Agency for Research in Cancer (WHO-IARC) has now declared hepatitis D, a little-known but deadly virus, carcinogenic, with the hope that it will lead to ...

Hepatitis D Virus (HDV) Particle. Image Made According To A View Under Transmission Electron Microscope, Viral Diameter 35 Nm. This is the first part of a series on hepatitis D virus, a virusoid-like ...

LA Times Studios produces content by working closely with scientists and healthcare experts as well as sourcing scholarly-reviewed medical and science journals and does not involve the Los Angeles ...

Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in hepatitis B while it seeks a suitable partner. Back in November, Vir arrived ...

It's unusual for presidents to give medical advice. But this week, President Trump told parents to delay giving their kids a ...

Whether hepatitis resolves depends on the type and whether a person receives treatment. Hepatitis A usually resolves without medications, and while sometimes hepatitis B and C may last only a few ...

In a press conference this week, President Trump said there's no reason to give babies the Hepatitis B vaccine. But pediatricians and infectious disease experts say this guidance is dangerous.

STOCKHOLM, Sweden, October 24, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has presented positive results from a preclinical study of its ...

World Hepatitis Day 2025 and its theme, “Hepatitis: Let’s Break It Down,” emphasize the urgent need to remove barriers to prevention, testing, and treatment to reduce liver cancer and eliminate ...

China has approved the world's first domestically developed drug designed to achieve a functional cure for hepatitis B, ...

Lawrence Blatt, Ph.D., CEO of Aligos Therapeutics, knows a thing or two about the slow drip of progress that has defined treating viral liver infections. He was “thrilled” back in the mid-90s when a ...